← 홈

Antibody · 혈액암 (AML/ALL)

286개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 286개
AntibodystaleRochePhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 RECRUITING
AntibodystaleAlliance for Clinical Trials in…Phase 2

Epratuzumab (Epratuzumab)

Lymphoma · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 DISCONTINUED
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.5%임상시험 28상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 76%임상시험 23상태 DISCONTINUED
AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5
효능 ORR 33.3%임상시험 23상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 3

zolbetuximab (zolbetuximab)

Gastric Cancer; Gastroesophageal Junction Adenocarcinoma · Locally Advanced Unresectable Gastroesop

#LocallyAdvancedUnresectableGastr#Antibody#Phase3#항체#면역항체+4
효능 ORR 48.1%임상시험 23상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

Linvoseltamab (Linvoseltamab)

Food Allergy · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Monalizumab (Monalizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 23.9%임상시험 22상태 RECRUITING
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab [KEYTRUDA®])

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · Metastatic Cancer

#MetastaticCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 40%임상시험 22상태 DISCONTINUED
AntibodystaleJanssen Research & Development,…Phase 2

Cetrelimab (Cetrelimab)

Carcinoma, Non-Small-Cell Lung · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+4
효능 ORR 75%임상시험 20상태 RECRUITING
AntibodystaleEli LillyPhase 2

Cetuximab + Gemcitabine + Oxaliplatin (Cetuximab + Gemcitabine + Oxaliplatin)

Cholangiocarcinoma; Adenocarcinoma of Gallbladder · Unresectable

#Unresectable#Antibody#Phase2#항체#면역항체+4
효능 ORR 5%임상시험 19상태 ACTIVE
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+3
효능 ORR 71.7%임상시험 19상태 RECRUITING
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
AntibodystaleRochePhase 3

Rituximab and Hyaluronidase Human (Rituximab and Hyaluronidase Human)

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 9%임상시험 18상태 RECRUITING
AntibodystaleBayerPhase 2

anetumab ravtansine (anetumab ravtansine)

Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#항체#면역항체+4
효능 ORR 7.2%임상시험 14상태 DISCONTINUED
AntibodystaleAmgenPreclinical

Dasatinib and blinatumomab (Dasatinib and blinatumomab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Preclinical#항체#면역항체+2
효능 ORR 10%임상시험 13상태 ACTIVE
AntibodystaleStemcentrxPhase 1

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

Small Cell Lung Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
효능 ORR 27.6%임상시험 13상태 ACTIVE
AntibodystaleLepu Medical Technology (Beijin…Phase 2

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma · Locally Advanced Oral and Oropharyngeal

#LocallyAdvancedOralandOropharyng#Antibody#Phase2#항체#면역항체+2
임상시험 11상태 RECRUITING
AntibodystaleMacroGenicsPhase 2

Flotetuzumab (Flotetuzumab)

Relapsed Acute Myeloid Leukemia · Relapsed Acute Myeloid Leukemia

#RelapsedAcuteMyeloidLeukemia#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 8상태 DISCONTINUED

3 / 15 페이지

← 이전다음 →